Morphic Medical Welcomes New Additions to Board of Directors

Morphic Medical, the revolutionary medical device company tackling the root cause of type 2 diabetes, is proud to announce the appointment of James Reinstein, Teresa Mattarelli, and John Barr to its Board of Directors.

These new additions bring a wealth of experience and expertise to Morphic Medical. James Reinstein, the President and CEO of Conformal Medical, has over 30 years of senior leadership in strategic planning, commercial excellence, and M&A. With previous roles at reputable medical device and diagnostic companies like Saranas Inc., Cutera Inc., and Drawbridge Health Inc., Reinstein is well-positioned to contribute to Morphic Medical's mission. "It is an honor to be part of Morphic Medical and support their mission to treat the underlying cause of metabolic diseases, including type 2 diabetes and obesity," said Reinstein.

Teresa Mattarelli joins the Board of Directors with a strong background in the healthcare industry. As the former Chief Commercial Officer of Perspectum Ltd., a precision health technology company, Mattarelli led the Obesity and Metabolic Health and Gynecological Health Business at Medtronic. Her experience spans various sectors, including med-tech, consumer packaged goods, and transportation. Mattarelli is excited about the opportunity to make a difference in the lives of patients suffering from metabolic diseases. "Type 2 Diabetes is a significant global health concern with a huge financial burden to the healthcare system," said Mattarelli.

John Barr, former Chairman of the Board for Apollo Endosurgery and an Operating Partner for Altamont Capital Partners, brings his expertise in private equity to Morphic Medical. With previous experience at Valeritas Holdings Inc., Surgical Specialties, Inc., and Bausch & Lomb Holdings Incorporated, Barr is well-versed in growing companies and driving innovation. "I am looking forward to working with the Morphic Medical executive team and board as the company advances its disruptive approach to bridge the gap between pharmaceuticals and surgery," said Barr.

Joe Virgilio, President and CEO of Morphic Medical, is thrilled to have these new additions to the Board of Directors. "We are excited to strengthen and further diversify the expertise of our Board with our newest members. Their proven leadership track records in growing life science companies and their extensive experience across multiple healthcare sectors including metabolic diseases," said Virgilio. "All three bring important perspectives and expertise to our company as we move towards commercialization of RESET, the first endoscopically delivered device therapy intended for patients unable to adequately control their metabolic disorders."

About Morphic Medical:

Morphic Medical is the developer of RESET, an endoscopically delivered device therapy offering a non-surgical, alternative treatment for type 2 diabetes and obesity. Founded in 2003 and headquartered in Boston, Massachusetts, Morphic Medical aims to help patients restore healthy blood sugar levels and reduce weight. Although RESET is not approved for sale in the United States and is limited to investigational use only, the company's groundbreaking approach shows tremendous promise in transforming the way metabolic diseases are treated.

For more information about Morphic Medical, please visit their website at morphicmedical.com. Stay updated by following them on Twitter and LinkedIn.

In conclusion, the addition of James Reinstein, Teresa Mattarelli, and John Barr to the Board of Directors strengthens Morphic Medical's expertise in advancing the treatment of metabolic diseases. With their proven leadership and experience, they will contribute to the company's mission of providing innovative solutions for patients with type 2 diabetes and obesity. Morphic Medical continues to make significant strides towards commercializing RESET, a revolutionary endoscopically delivered device therapy that aims to improve patient outcomes and reshape the field of metabolic disorder treatment.